

# REMINDER Injectables Meet the Management 24 March 2021, 2:00pm to 3:30pm

**London, 12 March 2021** – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, will host a series of 2021 'Meet the Management' events for investors and analysts.

The series will kick off with Injectables on Wednesday 24 March at 2:00pm GMT. The event will be hosted by Hikma's CEO, Siggi Olafsson, and feature a presentation and Q&A with senior leaders from our Injectables business segment.

Please register your attendance in advance by clicking <a href="here">here</a>.

The agenda for the day is as follows:

2:05 – 2:10pm	Welcome	Siggi Olafsson
2:10 – 2:20pm	Injectables overview	Riad Mechlaoui
2:20 – 2:30pm	US commercial	Joel Rosenstack
2:30 – 2:40pm	Operations	Frank Savastano
2:40 – 2:45pm	Wrap up	Riad Mechlaoui
2:45 – 3:30pm	Q&A	All speakers

# - ENDS -

## **Enquiries**

### **Hikma Pharmaceuticals PLC**

Susan Ringdal EVP, Strategic Planning and Global Affairs	+44 (0)20 7399 2760/ +44 7776 477050
Guy Featherstone Senior Investor Relations Manager	+44 (0)20 3892 4389/ +44 7795 896738
Layan Kalisse Investor Relations Analyst	+44 (0)20 7399 2788/ +44 7970 709912
uk-investors@hikma.uk.com	

# **About Hikma**

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody's)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the



people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com